Edoxaban compared with apixaban in people with atrial fibrillation and coronary artery disease
Compares edoxaban with apixaban in adults who have atrial fibrillation and coronary artery disease.
Plain-language title generated from the registry record
Registry title: Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Key facts
- Where
- Seoul, South KoreaSee the site
- Phase
- Phase 4
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Samsung Medical Center
- Trial code
- NCT07753200
- Record updated
- 10 August 2026
- Original description
Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.Read full original descriptionShow less
Net Clinical Benefit of Edoxaban Versus Apixaban in Patients With Atrial Fibrillation and Coronary Artery Disease
Non-vitamin K antagonist oral anticoagulants(NOACs) are standard care for thromboembolism prevention in patients with Aterial Fibrillation(AF). However, evidence comparing edoxaban and apixaban remains limited in AF patients with coexisting coronary artery disease(CAD). This study aims to evaluate whether edoxaban-based therapy is non-interior to apixaban-based therapy with respect to Net Adverse Clinical Events(NACE) in AF patients with concomitant CAD.
Inclusion: Patients must be at least 19 years of age; Patients with AF requiring oral anticoagulation therapy (CHA2DS2-VaSc 2 or more); Documented coronary artery disease, defined as at least one of the following: history of percutaneous coronary intervention (PCI), history of coronary artery bypass grafting (CABG), major epicardial coronary artery stenosis ≥50% on coronary computed tomography angiography (CCTA) or invasive coronary angiography; Patients who can understand risks, benefits and treatment alternatives and sign informed consent voluntarily.
Exclusion: Indication requiring alternative anticoagulation (e.g., mechanical valve surgery or moderate / severe mitral stenosis); Known hypersensitivity or contraindications to study medications (apixaban or edoxaban); Active major bleeding; Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment); Severe renal impairment (creatinine clearance <15 mL/min) or dialysis; Pregnant or lactating women.